Pharmaceutical - Financial, Ophthalmics

Filter

Current filters:

FinancialOphthalmics

Popular Filters

Italian legislation undermines EU regulatory framework by endorsing off-label drug use for economic reasons

Italian legislation undermines EU regulatory framework by endorsing off-label drug use for economic reasons

11-06-2014

The European Federation of Pharmaceutical Industries and Associations says it is concerned about a decision…

AvastinEuropeFinancialItalyNovartisOphthalmicsPharmaceuticalRegulationRoche

Avastin could save the USA $29 billion if used instead of Lucentis

Avastin could save the USA $29 billion if used instead of Lucentis

04-06-2014

Using Avastin (bevacizumab) from Swiss drug major Roche instead of Lucentis (ranibizumab) from fellow…

AvastinBevacizumabFinancialLucentisNovartisOphthalmicsPharmaceuticalRocheUSA

Shire 1st-qrt 2014 sales and earnings rocket; lifitegrast disappoints

01-05-2014

Ireland-headquartered drugmaker Shire posted a strong set of financials this afternoon, showing that…

FinancialLifitegrastOphthalmicsPharmaceuticalRare diseasesResearchShire

Roche and Novartis fined for cartelizing sales of eye drugs Avastin and Lucentis in Italy

Roche and Novartis fined for cartelizing sales of eye drugs Avastin and Lucentis in Italy

06-03-2014

Swiss pharma majors Roche and Novartis colluded to exclude the cheaper cancer drug Avastin (bevacizumab),…

AvastinEuropeFinancialItalyLegalLucentisNovartisOphthalmicsPharmaceuticalRoche

Company Spotlight

ImmunoGen

ImmunoGen

Back to top